Scarica l'app Stockscreener
1.6985
3.99%
0.0685
Precedente Chiudi:
$1.63
Aprire:
$1.65
Volume 24 ore:
4.79M
Relative Volume:
1.12
Capitalizzazione di mercato:
$156.71M
Reddito:
-
Utile/perdita netta:
$-69.31M
Rapporto P/E:
-1.3374
EPS:
-1.27
Flusso di cassa netto:
$-62.80M
1 W Prestazione:
-82.79%
1M Prestazione:
-82.83%
6M Prestazione:
-61.03%
1 anno Prestazione:
-62.25%
Intervallo 1D:
$1.64
$1.77
Intervallo di 1 settimana:
$1.07
$11.16
Portata 52W:
$1.07
$11.46
Rezolute Inc Stock (RZLT) Company Profile
Nome
Rezolute Inc
Settore
Industria
Telefono
650-206-4507
Indirizzo
275 SHORELINE DRIVE, SUITE 500, REDWOOD CITY
Confronta RZLT con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
RZLT
Rezolute Inc
|
1.69 | 151.15M | 0 | -69.31M | -62.80M | -1.27 |
|
VRTX
Vertex Pharmaceuticals Inc
|
454.97 | 115.62B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
736.63 | 79.10B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
846.04 | 52.39B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
390.75 | 51.72B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
INSM
Insmed Inc
|
201.26 | 42.00B | 447.02M | -1.18B | -906.14M | -6.1812 |
Rezolute Inc Stock (RZLT) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-12-11 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| 2025-12-11 | Downgrade | Craig Hallum | Buy → Hold |
| 2025-12-11 | Downgrade | Wedbush | Outperform → Neutral |
| 2024-11-05 | Iniziato | Wedbush | Outperform |
| 2024-08-27 | Iniziato | Guggenheim | Buy |
| 2024-07-17 | Iniziato | BTIG Research | Buy |
| 2024-06-04 | Iniziato | Craig Hallum | Buy |
| 2024-04-09 | Iniziato | Maxim Group | Buy |
| 2022-08-02 | Ripresa | Canaccord Genuity | Buy |
| 2022-06-15 | Iniziato | Cantor Fitzgerald | Overweight |
| 2021-09-08 | Iniziato | ROTH Capital | Buy |
| 2021-05-27 | Iniziato | Oppenheimer | Outperform |
| 2021-05-25 | Iniziato | H.C. Wainwright | Buy |
Mostra tutto
Rezolute Inc Borsa (RZLT) Ultime notizie
Elam Nevan C, Rezolute CEO, buys $50k in RZLT shares - Investing.com Australia
Entry Recap: Will Rezolute Inc stock outperform value stocksInflation Watch & AI Enhanced Trading Signals - moha.gov.vn
Rezolute CFO Evans buys shares worth $79,577 By Investing.com - Investing.com Canada
Elam Nevan C, Rezolute CEO, buys $50k in RZLT shares By Investing.com - Investing.com Canada
Daron Evans Buys 40,000 Shares of Rezolute (NASDAQ:RZLT) Stock - MarketBeat
Rezolute (NASDAQ:RZLT) Insider Purchases 12,100 Shares - MarketBeat
Nevan Elam Increases Stake in Rezolute Inc with Recent Share Pur - GuruFocus
Rezolute’s CCO Karnawat buys $19,598 in shares - Investing.com India
Rezolute CFO Evans buys shares worth $79,577 - Investing.com
Rezolute, Inc. (RZLT) Shares Tank 90% Amid Lead Asset Trial Failure — Hagens Berman Investigating RZLT Investors with Losses Encouraged to Contact the Firm - Morningstar
Down 81.8% in 4 Weeks, Here's Why Rezolute (RZLT) Looks Ripe for a Turnaround - Finviz
Rezolute downgraded to neutral from outperform at Wedbush - MSN
Rezolute (RZLT): Reassessing Valuation After sunRIZE Phase 3 Failure and Growing Legal Scrutiny - simplywall.st
INVESTOR ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Rezolute - TMX Newsfile
Rezolute price target raised to $20 from $15 at Jefferies - MSN
H.C. Wainwright Maintains Rezolute(RZLT.US) With Buy Rating, Maintains Target Price $5 - 富途牛牛
HC Wainwright Decreases Earnings Estimates for Rezolute - MarketBeat
Rezolute (RZLT) Is Down 82.7% After Phase 3 sunRIZE Failure in Congenital Hyperinsulinism Trial - Yahoo Finance UK
Rezolute shares collapse after phase 3 trial fails to meet main goals - MSN
Rezolute (NASDAQ:RZLT) Downgraded by Citizens Jmp to Hold - MarketBeat
Rezolute’s phase 3 study in congenital hyperinsulinism did not meet endpoints - MSN
Investors Buy Large Volume of Rezolute Call Options (NASDAQ:RZLT) - MarketBeat
Guggenheim Issues Pessimistic Forecast for Rezolute (NASDAQ:RZLT) Stock Price - MarketBeat
Jefferies Raises Rezolute Price Target Amid Favorable Data Prospects - timothysykes.com
SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Rezolute - TMX Newsfile
Wedbush downgrades Rezolute to neutral after congenital hyperinsulinism miss - MSN
Rezolute, Inc. (RZLT) Shares Tank 90% Amid Lead Asset Trial FailureHagens Berman Investigating - The Malaysian Reserve
Rezolute (NASDAQ:RZLT) Lowered to "Sell" Rating by Wall Street Zen - MarketBeat
Rezolute stock crashes after sole pipeline candidate fails Phase III - MSN
Rezolute (NASDAQ:RZLT) Reaches New 12-Month Low on Analyst Downgrade - MarketBeat
Guggenheim Maintains Rezolute (RZLT) Buy Recommendation - Nasdaq
Jefferies Raises Rezolute’s Price Target Amid Promising Drug Prospects - StocksToTrade
Is Rezolute Inc. (RZLT) One of the Top Long-Term Biotechnology Stocks to Buy - MSN
RZLT INVESTIGATION: Rezolute, Inc. Investors Should Contact Block & Leviton LLP To Potentially Recover Losses - TradingView — Track All Markets
Rezolute price target lowered to $4 from $20 at Maxim - MSN
Rezolute stock price target slashed by H.C. Wainwright after failed study - Investing.com Nigeria
Jefferies Lifts Rezolute’s Target amid New Data Anticipation - timothysykes.com
Craig-Hallum downgrades Rezolute stock to Hold on failed Phase III trial - Investing.com Australia
Rezolute Inc. trading resumes - MSN
Rezolute Inc trading halted, volatility trading pause - MSN
Rezolute decimated on Phase III miss for ersodetug - The Pharma Letter
Rezolute stock price target slashed by Guggenheim after trial failure - Investing.com Nigeria
RZLT Maintains Buy Rating despite Guggenheim's Lowered Price Tar - GuruFocus
Rezolute (RZLT) Stock Update Dec. 12, 2025: Phase 3 sunRIZE Miss Sparks Selloff, Analysts Reset Targets, and 2026 Catalysts - ts2.tech
Rezolute, Inc. (RZLT) Shares Tank 90% Amid Lead Asset Trial Failure -- Hagens Berman Investigating - PR Newswire
Craig-Hallum Downgrades Rezolute to Hold From Buy, Adjusts PT to $2 From $18 - marketscreener.com
Buy Rating Maintained for XOMA Despite Rezolute Bio’s Trial Setback, Future Developments Anticipated - TipRanks
Rezolute (RZLT): HC Wainwright & Co. Significantly Lowers Price Target | RZLT Stock News - GuruFocus
HC Wainwright & Co. Maintains Rezolute (RZLT) Buy Recommendation - Nasdaq
Rezolute price target lowered to $5 from $14 at H.C. Wainwright - TipRanks
What analysts say about Rezolute Inc 6HV1 stockProtective Put Strategies & Rapid Portfolio Growth - earlytimes.in
Rezolute Inc Azioni (RZLT) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Rezolute Inc Azioni (RZLT) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Evans Daron | CFO |
Dec 15 '25 |
Buy |
1.79 |
5,000 |
8,938 |
7,000 |
| Elam Nevan C | CEO |
Dec 15 '25 |
Buy |
1.59 |
32,000 |
50,880 |
641,119 |
| Karnawat Sunil Ratilal | Chief Commercial Officer |
Dec 15 '25 |
Buy |
1.62 |
12,100 |
19,599 |
71,542 |
| ROBERTS BRIAN KENNETH | Chief Medical Officer |
Jun 25 '25 |
Buy |
4.38 |
2,500 |
10,939 |
15,500 |
| Evans Daron | CFO |
Jun 24 '25 |
Buy |
4.05 |
5,000 |
20,250 |
268,900 |
| Kim Young-Jin | Director |
Jun 13 '25 |
Buy |
3.25 |
1,230,769 |
3,999,999 |
8,423,386 |
| KREHER NERISSA | Director |
Jun 13 '25 |
Buy |
3.25 |
3,076 |
9,997 |
37,576 |
| Hogenhuis Wladimir | Director |
Mar 31 '25 |
Buy |
2.92 |
6,758 |
19,733 |
84,025 |
| Elam Nevan C | CEO |
Mar 27 '25 |
Buy |
2.85 |
12,302 |
34,999 |
224,119 |
| Evans Daron | CFO |
Mar 26 '25 |
Buy |
2.89 |
10,000 |
28,900 |
237,900 |
0.42%
0.32%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):